NAD+ injection nausea safety guide

NAD+ injection nausea: what current evidence can—and cannot—say

Review nausea after NAD+ injection using current human IV evidence, route and compounding limits, other possible causes, medication review, dehydration checks, and urgent warning signs.

Educational guideUpdated July 30, 2026

A safer response to nausea after NAD+

Identify the exact exposure: patient-specific compounded NAD+ injection, a supervised IV infusion, nasal spray, oral NR or NMN, a mixed product, or research-use material that should not be used as human medication.

Record when nausea began, how severe it is, whether it follows each use, and whether vomiting, diarrhea, abdominal pain, headache, flushing, dizziness, fainting, chest pressure, fast heart rate, rash, swelling, or breathing symptoms occurred.

Assess hydration and illness context: ability to keep fluids down, urine frequency, fever, recent infection, food intake, alcohol, cannabis, travel, pregnancy possibility, and other people with similar symptoms.

Reconcile prescriptions, OTC medicines, vitamins, niacin, NR, NMN, stimulants, supplements, pre-workouts, alcohol, cannabis, and other longevity products before adding an anti-nausea product or changing treatment.

Contact the responsible prescriber for persistent, recurrent, severe, or treatment-limiting symptoms, and use urgent or emergency care for dehydration, bleeding, severe pain, cardiopulmonary, neurologic, or serious allergic warning signs.

Direct answer

Nausea has been reported during intravenous NAD+ administration, but human evidence does not establish how often compounded subcutaneous NAD+ injections cause nausea, how long it should last, or whether NAD+ caused an individual episode. In a small 2026 retrospective commercial-clinic pilot, all six people in the IV NAD+ group reported a cluster of moderate-to-severe symptoms that included nausea, vomiting, diarrhea, abdominal cramping, increased heart rate, throat discomfort, congestion, and chest pressure during infusions; those symptoms stopped when the infusions ended. That finding is preliminary IV tolerability evidence—not a side-effect rate or management rule for at-home injections, nasal products, oral precursors, or another formulation. New nausea should be reviewed with the exact product and route, symptom timing and severity, vomiting and hydration status, pregnancy possibility, recent illness, alcohol or cannabis use, and every medicine or supplement. Do not repeat, increase, slow, split, or switch a dose based on an online protocol. Persistent vomiting, inability to keep fluids down, reduced urination, fainting, severe abdominal pain, chest pain, trouble breathing, confusion, blood in vomit, or rapidly worsening illness needs prompt local assessment.

What the human evidence says

The clearest nausea signal comes from a tiny IV study—not injection trials

A 2026 retrospective pilot reviewed records from a commercial setting where clients received four consecutive days of IV NAD+ or IV nicotinamide riboside. All six people in the NAD+ group reported a symptom cluster that included moderate-to-severe abdominal cramping, diarrhea, nausea, vomiting, increased heart rate, throat discomfort, congestion, and chest pressure during infusion. Symptoms stopped when infusion ended. The study was small, nonrandomized, short, based in a commercial wellness setting, and its authors reported employment by the clinic company. It did not isolate nausea, establish a percentage applicable beyond those six people, or study Peptide12’s subcutaneous product.

Do not present six of six IV participants as a general “100% nausea risk”; it describes one very small selected group and a cluster of symptoms during a specific infusion protocol.
The paper did not establish a nausea-specific onset, duration, recurrence rate, treatment, or safe threshold for another route.
A separate 2026 critical review concluded that evidence for IV longevity therapies remains sparse, heterogeneous, and insufficient for evidence-based anti-aging practice.

Route and product identity

IV NAD+, compounded injections, nasal products, and oral precursors are not interchangeable

Intravenous infusion delivers NAD+ directly into a vein under staff supervision. A patient-specific compounded subcutaneous injection uses a different route, formulation, amount, absorption pattern, and care setting. NAD+ nasal products and oral nicotinamide riboside, NMN, niacin, or niacinamide are different exposures again. Evidence or side-effect timing from one cannot validate the quality, tolerability, or management of another. Compounded NAD+ is not an FDA-approved finished drug for nausea, fatigue, cognition, anti-aging, or longevity, and FDA does not review compounded drugs for safety, effectiveness, or quality before marketing in the same way it reviews approved drugs.

Confirm the active ingredient, route, concentration, other ingredients, dispensing pharmacy, patient-specific label, storage instructions, prescriber, and adverse-event contact.
Do not use a seller’s IV study to claim that a subcutaneous injection is proven safer, or use a subcutaneous testimonial to predict an IV response.
Avoid research-use vials, no-prescription checkout, unlabeled blends, copied dose charts, vague pharmacy sourcing, and claims that nausea proves cellular “detox” or NAD+ replenishment.

Other causes and medication review

Nausea after NAD+ does not automatically mean NAD+ is the cause

Nausea is nonspecific. Viral or foodborne illness, migraine, reflux, constipation, pregnancy, anxiety, dehydration, alcohol, cannabis, another medicine, a supplement, or an underlying abdominal, metabolic, kidney, liver, cardiac, or neurologic problem may be responsible or may worsen symptoms. Niacin can cause flushing and gastrointestinal effects, but niacin is a vitamin B3 form—not interchangeable evidence for compounded NAD+ injection. A clinician should review the full timeline rather than attributing every symptom to a normal “flush” or “detox.”

List diabetes and weight medicines, antibiotics, pain medicines, antidepressants, stimulants, blood-pressure medicines, migraine products, vitamins, niacin, NR, NMN, iron, magnesium, pre-workouts, alcohol, cannabis, and other wellness products.
Share pregnancy possibility, recent illness or travel, migraine history, reflux, severe constipation, abdominal surgery, diabetes, kidney or liver disease, and prior injection or infusion reactions.
Do not stop a prescription, add an anti-nausea medicine, use cannabis, or combine NAD-related products to manage symptoms without clinician or pharmacist review.

Monitoring and escalation

Use symptom severity and hydration—not an online countdown—to decide the next step

The available NAD+ literature does not provide a validated countdown for nausea after a compounded injection. Mild, brief symptoms still deserve documentation and prescriber guidance before another treatment decision. Recurrent nausea, repeated vomiting, or worsening symptoms can cause dehydration and may signal another problem. The responsible clinician should explain who reviews symptoms, whether treatment pauses, which records or measurements are needed, and when local care is more appropriate than portal messaging.

Seek prompt assessment for persistent vomiting, inability to keep fluids down, markedly reduced urination, fainting, severe weakness, severe abdominal pain, blood or coffee-ground material in vomit, black stools, fever with worsening illness, or pregnancy-related concerns.
Use emergency services for chest pain, severe trouble breathing, confusion, seizure, new weakness or speech change, or severe allergic symptoms such as facial or throat swelling.
Report a serious product problem through the prescriber, dispensing pharmacy, and FDA MedWatch when appropriate; preserve the label, lot information, packaging, and symptom timeline.

Patient safety checklist

Questions to ask about nausea after NAD+ injection

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Was this a patient-specific compounded NAD+ injection, supervised IV infusion, nasal product, oral precursor, mixed formulation, or research-use product?

✓

What are the active ingredient, concentration, other ingredients, route, dispensing pharmacy, lot information, storage instructions, and prescriber contact on the label?

✓

When did nausea begin, how severe is it, how long has it lasted, does it recur, and did vomiting, diarrhea, abdominal pain, headache, flushing, dizziness, fainting, chest pressure, palpitations, rash, swelling, or breathing trouble occur?

✓

Can I keep fluids down, am I urinating normally, and do fever, illness exposure, recent travel, food intake, alcohol, cannabis, migraine, reflux, constipation, or pregnancy possibility change the review?

✓

Which prescriptions, OTC medicines, vitamins, niacin, NR, NMN, supplements, pre-workouts, energy products, alcohol, and cannabis products am I using?

✓

Could another medicine, infection, pregnancy, migraine, dehydration, abdominal condition, kidney or liver problem, or another diagnosis better explain the symptom?

✓

Who decides whether treatment pauses, stops, or continues, and which symptoms require a portal message, same-day visit, urgent care, poison control, or emergency services?

✓

Does the clinic avoid copied dose charts, “detox” explanations, guaranteed nausea prevention, research-use products, hidden pharmacy sourcing, and advice to push through severe symptoms?

FAQs

Short answers for patients

Can NAD+ injections cause nausea?

Nausea has been reported with NAD+ administration, but current human evidence does not establish a reliable rate for compounded subcutaneous injections. The clearest recent study involved only six IV NAD+ participants and cannot be converted into an at-home injection risk estimate.

How long does nausea after an NAD+ injection last?

There is no validated duration estimate for nausea after compounded NAD+ injection. In the small 2026 IV pilot, the reported symptom cluster stopped when infusions ended, but that does not create a countdown for another route. Persistent, recurrent, severe, or treatment-limiting nausea should be reviewed before another treatment decision.

Does nausea mean the NAD+ is working or detoxing me?

No. Nausea is not proof of detoxification, cellular repair, absorption, or benefit. It can reflect a product reaction, another medicine, dehydration, illness, pregnancy, migraine, gastrointestinal disease, or another condition that needs assessment.

Should I change or repeat my NAD+ dose after nausea?

Do not repeat, increase, split, slow, retime, or switch routes based on an online chart. Contact the responsible prescriber with the exact label, symptom timeline, hydration status, other products, and red flags so the next decision is individualized.

Can I take an anti-nausea medicine after NAD+?

Ask a clinician or pharmacist first. Ondansetron, antihistamines, bismuth products, cannabis, ginger supplements, and other remedies can have their own contraindications, interactions, sedation effects, or masking risks. The cause and severity of nausea matter more than adding a generic remedy.

Are IV NAD+ nausea findings the same for subcutaneous injections?

No. IV infusion and subcutaneous injection differ in route, formulation, exposure, setting, and monitoring. The 2026 IV pilot is a cautionary tolerability signal, not proof of the frequency, duration, or management of nausea from compounded injections.

When is nausea after NAD+ urgent?

Prompt local assessment is appropriate for persistent vomiting, inability to keep fluids down, reduced urination, fainting, severe abdominal pain, blood in vomit, black stools, worsening fever, pregnancy concerns, or rapidly worsening illness. Chest pain, severe trouble breathing, confusion, seizure, new neurologic symptoms, or severe facial or throat swelling warrants emergency care.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

PMC: 2026 retrospective tolerability pilot of IV NAD+ versus IV nicotinamide riboside PubMed: Intravenous longevity therapy—critical review of evidence and clinical utility MedlinePlus: Nausea and vomiting NIH Office of Dietary Supplements: Niacin fact sheet for health professionals FDA: Compounding and the FDA—Questions and Answers FDA MedWatch: Report a serious problem with a medical product Peptide12: Compounded NAD+ injection Peptide12: NAD+ side effects Peptide12: NAD+ injection vs IV drip Peptide12: NAD+ injection and blood pressure Peptide12: Nausea medication review Peptide12: Hydration and electrolytes Peptide12: When in-person care is needed Peptide12: How online peptide therapy works